Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
39
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Beyond Milan Criteria
Interventions
DRUG:
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1
Sponsor
Sun Yat-sen University